STOCK RADAR
Detected
SLNONasdaq Trader

Soleno Therapeutics, Inc. merger closes with trading suspension set for May 19, 2026

Strategic TransactionneutralImpact80

SLNO Price

Stored market data
$53.01$0.00 (0.00%)
$53.13$53.00$52.87Previous close4:15 AM10:25 AM12:05 PM1:50 PM3:30 PM7:35 PMVolume
Previous close $53.01Latest volume 1.9K

Why It Matters

Current holders will be cashed out at $53.00 per share and lose tradable shares, liquidity, and any future upside.

Summary

Add Stock Radar as a preferred source on GoogleAdd Stock Radar on Google

A Neurocrine subsidiary's tender offer expired May 15 and the merger closed May 18. Last trading date was May 15 and the stock is suspended effective May 19; holders will receive $53.00 per share in cash, eliminating tradable equity.

Score80

Score Rationale

neutral

Known cash-out with delisting and trading suspension materially changes tradability, liquidity, and ownership.

Bullish

  • Guaranteed $53 per share cash consideration.
  • Removes ongoing execution and operational risk for holders.
  • Short, defined timeline to receive cash proceeds.

Bearish

  • Equity will be delisted and suspended, removing market access.
  • Any upside above $53.00 per share is eliminated.
  • Shareholders who miss tender may face inability to sell before suspension.
  • Proceeds may have tax and timing consequences for holders.

Key Evidence

  • Tender offer expired one minute after 11:59 p.m. ET on May 15, 2026.
  • Merger closed prior to market open on May 18, 2026.
  • Stock halted after-hours around 7:50 p.m. ET May 15 and suspended effective May 19, 2026.
  • Merger consideration $53.00 per share; last trading date May 15, 2026.

What To Watch Next

  1. Confirm cash payment/settlement date with broker or transfer agent.
  2. Check brokerage account for cash posting timing and settlement.
  3. Watch Nasdaq for delisting confirmation and removal from listings.
  4. Expect tax reporting and cost-basis information from broker.
AdvertisementResponsive display
AdvertisementRemove ads
AdvertisementResponsive display
AdvertisementRemove ads

healthcare_momentum Market Context

SectorHealthcare+0.70%
IndustryBiotechnology-1.26%
Themehealthcare_momentum
AdvertisementResponsive display
AdvertisementRemove ads
AdvertisementResponsive display
AdvertisementRemove ads

Original Article

The tender offer by a subsidiary of Neurocrine Biosciences to acquire all of the outstanding common stock of Soleno Therapeutics, Inc. (SLNO) expired one minute following 11:59 p.m. ET, on May 15, 2026. The subsequent merger closed prior to the market open on May 18, 2026. In anticipation of the closing, the stock was halted immediately following the after-hours session at or around 7:50 p.m. on May 15, 2026. The stock will remain halted on the day of closing (May 18th) and will be suspended effective May 19, 2026. The details are as follows:

Company/Issue: Soleno Therapeutics, Inc. Common Stock
CUSIP#: 834203309
Symbol: SLNO
Last Trading Date: May 15, 2026
Marketplace Effective Date for Suspension: May 19, 2026
Merger Consideration: $53.00 for each share held.